No headlines found.
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
Globe Newswire (Thu, 27-Mar 8:30 AM ET)
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
Globe Newswire (Tue, 18-Mar 5:33 PM ET)
Globe Newswire (Thu, 6-Mar 9:30 AM ET)
Globe Newswire (Tue, 25-Feb 8:30 AM ET)
Globe Newswire (Mon, 24-Feb 8:30 AM ET)
Globe Newswire (Tue, 11-Feb 8:30 AM ET)
Globe Newswire (Wed, 5-Feb 8:15 AM ET)
Globe Newswire (Tue, 21-Jan 8:15 AM ET)
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Oragenics trades on the AMEX stock market under the symbol OGEN.
As of March 28, 2025, OGEN stock price declined to $0.22 with 260,413 million shares trading.
OGEN has a beta of 3.72, meaning it tends to be more sensitive to market movements. OGEN has a correlation of 0.12 to the broad based SPY ETF.
OGEN has a market cap of $4.64 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, OGEN traded as high as $25.20 and as low as $.21.
The top ETF exchange traded funds that OGEN belongs to (by Net Assets): VXF.
OGEN has underperformed the market in the last year with a price return of -85.0% while the SPY ETF gained +7.6%. OGEN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -52.3% and -22.8%, respectively, while the SPY returned -6.3% and -1.0%, respectively.
OGEN support price is $.22 and resistance is $.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OGEN shares will trade within this expected range on the day.